ABSTRACT
Over the last three decades, extensive basic and clinical research has been performed on the use of subthalamic nucleus (STN) as the preferred deep brain stimulation (DBS) target for the treatment of Parkinson’s disease (PD). The mechanism underlying the benefit for the motor symptoms in PD is related to the modulation of firing patterns within the hyperdirect projections from motor cortical areas, as well as within the afferent and efferent fibers to the motor STN. Advancements in neuroimaging techniques allow us to identify precisely the STN optimizing surgical targeting. In this review, we provide an update on the current uses of STN-DBS as a routine therapy as well as its experimental indications in PD, the critical aspects associated with its successful implementation and recent advances in DBS technology.
Article Highlights
The subthalamic nucleus (STN) is still the primary target of Deep Brain Stimulation (DBS) for Parkinson’s disease (PD).
Cognitive decline and dopa refractory axial symptoms are not improved by this surgical procedure.
Age, severity of PD, and lead location are important predictors of long-term improvement.
Innovative techniques, such as short pulse width stimulation and directional DBS, may allow some reduction in stimulation-related side effects.
Declaration of Interest
P Limousin, L Zrinzo, & T Foltynie have received honoraria/travel expenses from Boston Scientific, Elekta, and Medtronic for speaking at educational meetings. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer Disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.